KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$2.0 million.

  • Nektar Therapeutics' Net Cash Flow fell 18907.6% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 13129.11%. This contributed to the annual value of $9.0 million for FY2024, which is 11693.77% up from last year.
  • Nektar Therapeutics' Net Cash Flow amounted to -$2.0 million in Q3 2025, which was down 18907.6% from $4.1 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Net Cash Flow high stood at $42.8 million for Q1 2022, and its period low was -$98.3 million during Q3 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$2.0 million (2025), whereas its average is -$8.3 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 387023.42% in 2021, then skyrocketed by 33381.42% in 2022.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Net Cash Flow stood at -$28.8 million in 2021, then surged by 38.91% to -$17.6 million in 2022, then plummeted by 68.61% to -$29.7 million in 2023, then surged by 147.59% to $14.1 million in 2024, then tumbled by 113.87% to -$2.0 million in 2025.
  • Its Net Cash Flow was -$2.0 million in Q3 2025, compared to $4.1 million in Q2 2025 and -$5.4 million in Q1 2025.